Plexium launches with $28M Series A financing to advance DELPhe platform, cell-based screening of DNA-encoded libraries in nanoliter volumes, to discover novel E3 ligase-modulating drugs bit.ly/2OP8Guh #biotech #drugdiscovery #cancer #oncology #neurodegeneration

.Plexium, launched Thursday with a $28M series A, is combining DNA-encoding libraries with cell-based screens to find compounds that induce target degradation buff.ly/2IZ12d2

Drugging the Undruggable: A Talk with Plexium’s Swamy Vijayan hubs.ly/H0llfdy0

Plexium CEO Kandaswamy Vijayan to present on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” at the 2nd Targeted Protein Degradation Summit on Oct. 23 at 12:30 pm: bit.ly/2VW40Ej #biotech #drugdiscovery #cancer #oncology #neurodegeneration #Boston

Don’t miss Plexium CEO Kandaswamy Vijayan’s presentation on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” today at the 2nd Targeted Protein Degradation Summit: bit.ly/2VW40Ej #biotech #drugdiscovery #drugdevelopment #cancer #oncology #neurodegeneration #Boston

Big news today – we closed a $35M financing w/ Lux Capital, Pivotal Bioventures, The Column Group, DCVC and other outstanding investors to help us advance our pipeline of novel protein degraders. We’re also thrilled to welcome Mike Grey as Chairman! prn.to/39QkchL

Our approach to TPD is highlighted in poster #1283 at this year's AACR meeting. We describe the discovery & unique profile of a non-PROTAC selective degrader of BRD4 for the treatment of myc-driven tumors. "Discovery of potent & selective degraders of BRD4 using DELPhe platform"

#Plexium is looking to expand our team of drug hunters, with openings for positions such as Principal Scientist and Process Engineer! Check out our careers page for more details! #proteindegradation